Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsSuven pharma

    Suven Pharma

    Jump to

    • Suven Pharma Consolidated December 2024 Net Sales at Rs 307.15 crore, up 39.73% Y-o-Y

    • Suven Pharma shares snap four-day losing streak, up 10% on solid Q3 earnings

      The key driver behind this growth was its pharma CDMO business, which recorded a remarkable 101 percent year-on-year increase, fueled by ongoing research and development efforts and business expansion initiatives.

    • Advent’s rush to scale up Suven Pharma leads it to another acquisition

      The NJ Bio acquisition follows Sapala Organics purchase in June

    • Suven Pharma Consolidated September 2024 Net Sales at Rs 257.72 crore, up 11.54% Y-o-Y

    • Suven Pharma Standalone September 2024 Net Sales at Rs 236.06 crore, up 5.09% Y-o-Y

    • Suven Pharma hits 52-week high as USFDA closes inspection of unit Casper Pharma

      In July, Suven Pharma had received a Form 483 from USFDA, with two observations regarding Casper Pharma, which the company said were procedural in nature, assuring these would be addressed in stimulated time.

    • Stock Radar: Suzlon Energy, SpiceJet, Ola Electric, Mazagon Dock, Gala Precision Engg in focus on Monday

      Stocks like Godfrey Phillips, Deep Industries, RBM Infracon, Granules India and Suven Pharma will also be in focus on Monday.

    • Suven Pharma Consolidated June 2024 Net Sales at Rs 230.69 crore, down 33.62% Y-o-Y

    • Suven Pharma Standalone June 2024 Net Sales at Rs 222.09 crore, down 35.44% Y-o-Y

    • Suven Pharma Consolidated March 2024 Net Sales at Rs 252.93 crore, down 31.52% Y-o-Y

    • Suven Pharma to acquire 67.5% stake in Sapala Organics for Rs 229.5 crore

      Sapala reported a revenue of around Rs 67 crore for FY24. Shares of Suven Pharma ended 0.63 per cent lower at Rs 667.25 apiece on the BSE

    • Suven Pharma Standalone March 2024 Net Sales at Rs 243.52 crore, down 33.17% Y-o-Y

    • Why Suven Pharma’s investors are excited about Cohance Lifesciences

      The current vendor diversification drive by big pharma is driving large business opportunities for Indian CDMOs

    • Suven Pharma zooms 12% on merger with Cohance Lifesciences

      Suven Pharmaceuticals Limited on February 29 announced a scheme of amalgamation for merger with Cohance Lifesciences Limited

    • Suven Pharma, Cohance Lifesciences announce merger

      The overall transaction is expected to conclude over the next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals.

    • Suven Pharma Consolidated December 2023 Net Sales at Rs 219.82 crore, down 37.86% Y-o-Y

    • Suven Pharma Standalone December 2023 Net Sales at Rs 212.83 crore, down 38.93% Y-o-Y

    • Suven Pharma tanks 10% on poor Q3 show, sharp margin erosion

      Suven Pharma reported a sharp decline in its net profit, revenue and profitability in Q3.

    • Suven Pharma Q3 results: Net profit down 57% YoY to Rs 47 crore

      The pharma company expects that the next few quarters to continue to be soft due to the impact of global destocking in specialty chemicals and FY23 base effect

    • Suven Pharma Standalone September 2023 Net Sales at Rs 224.62 crore, down 19.32% Y-o-Y

    • Suven Pharma Q2 results: Net profit up 10% YoY to Rs 79.5 crore

      Suven Pharmaceuticals Ltd had reported a 12.2 percent year-on-year (YoY) rise in net profit at Rs 120.6 crore for the first quarter that ended June 30, 2023

    • Suven Pharma soars 6% as cabinet committee greenlights Rs 9,589 crore FDI deal

      The approval is for the acquisition of up to 76.1 percent stake in Suven Pharmaceuticals by Cyprus-based Berhyanda Ltd.

    • Suven Pharma gains on healthy Q1 show, strong operational performance

      The highlight of Suven Pharma's Q1 earnings was the company's sharp margin improvement

    • Suven Pharma Consolidated June 2023 Net Sales at Rs 347.55 crore, up 2.58% Y-o-Y

    • Suven Pharma Standalone June 2023 Net Sales at Rs 344.03 crore, up 1.54% Y-o-Y

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347